MAYNF (Mayne Pharma Group) Total Operating Expense: $228.2 Mil (TTM As of Dec. 2025)


MAYNF Mayne Pharma Group Ltd MAYNF
48 GF Score
Price $1.65
GF Value $3.87
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mayne Pharma Group Total Operating Expense?

Mayne Pharma Group MAYNF 48 Total Operating Expense is $228.2 Mil as of Dec. 2025. GuruFocus rates MAYNF with a GF Score™ of 48/100 and a GF Value™ of $3.87 (Possible Value Trap). The stock has 3 warning signs investors should review.

Mayne Pharma Group's Total Operating Expense for the six months ended in Dec. 2025 was $126.4 Mil. Mayne Pharma Group's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $228.2 Mil.

Mayne Pharma Group Total Operating Expense Related Terms

Mayne Pharma Group Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Mayne Pharma Group's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mayne Pharma Group Total Operating Expense Chart

Mayne Pharma Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 148.36 178.00 183.20 237.44 192.58

Mayne Pharma Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.46 145.72 88.37 101.73 126.43
MAYNF
48GF Score
Mayne Pharma Group Ltd MAYNF
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mayne Pharma Group Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $228.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $228.2 Mil mean?
Mayne Pharma Group (MAYNF) has a Total Operating Expense of $228.2 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Mayne Pharma Group and its competitors.
Is Mayne Pharma Group's Total Operating Expense too high?
Mayne Pharma Group's current Total Operating Expense is $228.2 Mil. Overall, Mayne Pharma Group has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Total Operating Expense compare to MCK and CAH?
Mayne Pharma Group's Total Operating Expense of $228.2 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Distribution company?
A good Total Operating Expense depends on the Medical Distribution industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Mayne Pharma Group and its competitors. Mayne Pharma Group's current Total Operating Expense is $228.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.87, compared to a current price of $1.65 — trading 57.4% below its estimated fair value. The current Total Operating Expense is $228.2 Mil. Mayne Pharma Group's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current Total Operating Expense is $228.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mayne Pharma Group (MAYNF) Overvalued in 2026?

Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued. The current stock price of $1.65 is trading 57.4% below its estimated GF Value™ of $3.87. GuruFocus considers Mayne Pharma Group to be Possible Value Trap.

Key valuation signals for MAYNF:

  • Total Operating Expense: $228.2 Mil
  • GF Value™: $3.87 vs. price of $1.65 (57.4% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mayne Pharma Group Business Description

Other Exchanges MYX:Australia
Address 1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
48GF Score

Get the complete analysis for MAYNF

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65
Price
$3.87
GF Value